Two Phase III trials show bevacizumab benefit for ovarian cancer

2011 ◽  
Vol 8 (7) ◽  
pp. 4
Author(s):  
&NA;
Keyword(s):  
Ovarian Cancer ◽  
Phase Iii ◽  
Two Phase ◽  
Phase Iii Trials

National Cancer Institute–United States strategy regarding intraperitoneal chemotherapy for ovarian cancer

2008 ◽  
Vol 18 (Suppl 1) ◽  
pp. 26-28 ◽  
Author(s):  
E. L. Trimble ◽  
M. C. Christian
Keyword(s):  
Ovarian Cancer ◽  
National Cancer Institute ◽  
Phase Iii ◽  
Cooperative Groups ◽  
Advocacy Organizations ◽  
Increased Risk ◽  
Phase Iii Trials ◽  
Educational Campaign ◽  
Clinically Significant ◽  
Further Development

On the basis of three large randomized phase III trials, the National Cancer Institute (NCI) issued a Clinical Announcement in January 2006 recommending that women with optimally debulked stage III ovarian cancer and their physicians consider a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy. The combination of IV and IP chemotherapy is associated with a clinically significant benefit in survival, although it does also confer an increased risk of toxicity compared to IV chemotherapy alone. The NCI Clinical Announcement was issued as part of a broader educational campaign, designed in conjunction with professional societies, cancer centers, Clinical Trials Cooperative Groups, and cancer advocacy organizations. The further development of IP chemotherapy in ovarian cancer requires additional clinical and translational research

scholarly journals First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

ESMO Open ◽  
2020 ◽  
Vol 5 (6) ◽  
pp. e001110
Author(s):  
Susana Banerjee ◽  
Antonio Gonzalez-Martin ◽  
Philipp Harter ◽  
Domenica Lorusso ◽  
Kathleen N Moore ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Maintenance Therapy ◽  
Parp Inhibitor ◽  
Advanced Ovarian Cancer ◽  
Round Table ◽  
Parp Inhibitors ◽  
Phase Iii ◽  
European Medicines Agency ◽  
First Line ◽  
Phase Iii Trials

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.

Ovarian Cancer Phase III Trials

2007 ◽  
Vol 29 (Supplement) ◽  
pp. 8-10
Author(s):  
Rabiya S. Tuma
Keyword(s):  
Ovarian Cancer ◽  
Phase Iii ◽  
Phase Iii Trials

scholarly journals Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

Ophthalmology ◽  
2013 ◽  
Vol 120 (10) ◽  
pp. 2013-2022 ◽  
Author(s):  
David M. Brown ◽  
Quan Dong Nguyen ◽  
Dennis M. Marcus ◽  
David S. Boyer ◽  
Sunil Patel ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Phase Iii ◽  
Long Term Outcomes ◽  
Two Phase ◽  
Phase Iii Trials
Sign in / Sign up

Export Citation Format

Share Document